Vascarta Welcomes Richard Serbin as Chief Strategy Officer to Lead Growth Initiatives

Vascarta Strengthens Leadership with Richard Serbin

June 9, 2026, Summit, N.J. – Vascarta Inc., a prominent player in the pharmaceutical industry, proudly announces the addition of Richard Serbin to its leadership team as the Chief Strategy Officer. This appointment is expected to significantly enhance Vascarta's position as a trailblazer in healthcare innovations.

Richard Serbin, an accomplished executive with more than 50 years in the pharmaceutical sector, brings a wealth of experience to Vascarta. His previous role as the Executive Vice President of Corporate Development at Johnson & Johnson equips him with the insight needed to navigate the complexities of strategic partnerships and acquisitions. In this new role, Serbin will collaborate closely with Vascarta's existing leadership to explore pioneering opportunities for growth and collaboration.

Mr. Serbin's background is as impressive as it is diverse. He is a trained regulatory attorney, patent attorney, and pharmacist, having served in pivotal positions at renowned companies such as Schering-Plough Corporation, Revlon, and Johnson & Johnson. His expertise includes dealing with FDA affairs and spearheading licensing and acquisition strategies that have had lasting impacts on the companies he has worked for.

In his statement about the appointment, Vascarta’s CEO, Dr. Richard Prince, expressed enthusiasm about Serbin joining the team. “We are thrilled to welcome Richard into our fold. His extensive experience and established reputation in drug development will be invaluable as we work on growth initiatives and the strategic development of our offerings,” he said. Dr. Prince noted that Serbin’s proven track record of identifying and commercializing innovative therapies aligns perfectly with Vascarta's mission to meet unmet medical needs through the exploration of advanced therapies.

Vascarta is at the forefront of developing clinical-stage pharmaceuticals aimed at achieving effective transdermal delivery methods. The company's pioneering work focuses initially on treating inflammatory conditions such as sickle cell disease and osteoarthritis. With a strong commitment to improving patient outcomes, Vascarta is dedicated to addressing challenges in the healthcare landscape.

Before his tenure at Johnson & Johnson, Richard Serbin was instrumental in establishing multiple medical communication companies that have since been acquired by larger international organizations. His strategic planning acumen, coupled with his extensive contacts within the healthcare community, positions Vascarta to potentially alter the course of treatment for conditions currently facing procedural difficulties.

In addition to his executive roles, Serbin has held positions on the Board of Directors for 16 subsidiaries of Johnson & Johnson across both domestic and international markets, underscoring his broad influence in the industry. His hands-on approach to business development and regulatory compliance is expected to drive Vascarta's upcoming projects.

Looking Ahead

With Richard Serbin now part of the leadership team, Vascarta is set to bolster its research and development endeavors. The pharmaceutical landscape is evolving rapidly, and the company aims to remain agile in adapting to these changes. Vascarta's innovative strategies under Serbin's guidance could pave the way for groundbreaking advancements in healthcare delivery.

In conclusion, Richard Serbin represents not just an addition to the team but a significant step toward realizing Vascarta’s ambitious goals in pharmaceutical development and regulatory excellence. As the company continues to seek strategic partnerships and acquisitions, Serbin's presence will be felt in every corner of its operations. For more details about Vascarta and its offerings, please visit www.vascarta.com.